Credits: Canva
As per the latest data released by Transforming Access to Student Outcomes in Higher Education (TASO) and the Policy Institute at King's College London, the number of UK students reporting mental health difficulties tripled. The estimate reveals that around 300,000 students could now be experiencing mental health struggles. Of the total, 18% of students reported some kind of mental health issue in 2024.
As per the reports, this estimate is triple what was reported in 2017, where it was at 6%. Experts also say that Covid-19 pandemic is "often considered to have contributed to this, it does not explain the ongoing rise in mental health difficulties." Another reason could also be the "changing definition and increasing openness about mental health" which has led to a rise in numbers. The report notes, "This trend pre-dates the Covid-19 pandemic and the cost-of-living crisis. Although these factors play a part in students' deteriorating mental health, they cannot therefore be the only explanation."
The report drew data collected over the latest Student Academic Experience Survey of 93,212 students. From the survey, it was found that there exist significant disparities between demographic groups, with women being twice as likely to report mental health difficulties, about 22% as compared to men, at 11%.
The results revealed that students who identified as LGBTQ experienced the highest rates of mental health challenges. This has actually lessened the hope that conditions for LGBTQ students are improving, which may not have been a positive case.
Of them, 42% are bisexual and lesbian students, whereas last year it was 35% and 32% respectively. The report also noted that mental health difficulties among lesbian women and gay men rose three times the rate of straight people, and among bisexual and asexual people, it was twice as high. For trans students, the number jumped from 25% in 2023 to 40% in 2024.
As per the Child Mind Institute, being LGBTQ+ does not cause mental health problems, but because these kids often face factors like rejection, discrimination and violence, they are at a higher risk of challenges including depression, anxiety, and even attempting suicide.
A UTAH Health study quotes Anna Docherty, PhD, LP, assistant professor of psychiatry at Huntsman Mental Health Institute that, "likely with any identity, feeling different - or worse, unaccepted as you are is a significant risk factor of mental health struggle." The data reveals that LGBTQ+ teens are six times more likely to experience symptoms of depression than non-LGBTQ+ identifying teens. They are also more than twice as likely to feel suicidal and more than four times as likely to attempt suicide. In the US alone, 48% of transgender adults report that they have considered suicide in the last year, compared to 4% of the overall population.
TASO's academic lead and professor of public policy at King's College London, Michael Sanders said, "LGBTQ students and women bear the brunt of the rise in declining mental health and urgent action is needed to understand and address these trends."
Credit: AI
Illegal horse trade across the US-Mexico border are raising fresh concerns among US officials and ranchers as the country tries to contain the spread of New World screwworm, a flesh-eating parasite that can cause severe and possibly fatal wounds in animals.
According to Reuters, horses and other animals are continuing to cross the border outside regulated channels, bypassing veterinary inspections designed to detect diseases and parasites.
There is no confirmed link between individual smuggled horses and specific screwworm cases, but experts warn that uncontrolled animal movement creates a gap.
Unlike ordinary maggots that generally feed on dead tissue, screwworm larvae feed on living tissue, creating wounds that can become severe as more larvae develop. The parasite can infest cattle, horses, pets and wildlife and, more rarely, humans. An untreated infestation can cause serious tissue damage and death.
The US had previously eradicated the parasite through a decades-long campaign involving the release of sterilised male flies. But New World screwworm has been moving northward through Mexico and is now threatening US livestock again.
Also read: Wegovy & Zepbound Are Not Approved By US FDA For Children Under 12: So Why Are Prescriptions Rising?
Animals entering the US through legal channels undergo veterinary checks and must meet health requirements. Smuggled animals can bypass those safeguards.
Reuters reported that authorities in Presidio County, Texas, have intercepted more than 50 smuggled horses over two years. Some were reportedly moved through remote areas along the Texas-Mexico border, making them difficult to monitor.
That matters because an infected animal can potentially carry screwworm larvae or adult flies into new areas.
USDA officials have described animal trafficking as a biosecurity concern. However, authorities have not established that illegally transported horses are responsible for particular screwworm infections in the US.
The parasite was previously eliminated from the US, making its recent return a major agricultural concern.
The USDA says New World screwworm is a devastating pest capable of causing serious, often deadly damage to livestock. It can also affect pets, wildlife and, in rare circumstances, people.
The economic consequences include potential damage from a major Texas outbreak at up to $1.8 billion, reflecting losses to livestock and related industries.
The threat comes as the US is also navigating the difficult balance between controlling screwworm and maintaining livestock trade with Mexico.
In August, the US began a phased reopening of Mexican cattle imports after a more than year-long suspension linked to the screwworm threat. Mexico has simultaneously been releasing sterile flies and other containment efforts along its northern border.
One of the main tools is the sterile insect technique. Large numbers of male screwworm flies are sterilised and released into affected areas. When they mate with wild females, they produce no viable offspring, helping reduce the population.
As of September 4, the agency said the current risk to animals and people in the US remained very low, and stressed that screwworm is not a food-safety issue. But illegal animal trade complicates those efforts.
Credit: AI
The use of GLP-1 medications weight-loss medications among children under 12 in the US has risen in recent years, according to a new study. This has raised questions about how these drugs should be used in younger children and what is known about their long-term effects.
Researchers studied health records from more than 3.5 million children aged 8 to 11 with obesity and found that prescriptions for GLP-1 medications increased more than 300-fold between 2019 and June 2026.
In 2019, only about 0.03% of children in the study group had been prescribed a GLP-1 drug. By June 2026, that figure had risen to 9.3%.
The medications included drugs like Wegovy and Saxenda, made by Novo Nordisk, and Eli Lilly's Zepbound.
The researchers used data from Epic Cosmos, a large electronic health-record database covering patients across the US. Epic was not involved in the study.
Also read: The New Nutrition Gap: Why Knowing What To Eat Doesn't Mean We Actually Eat It
The rise does not appear to represent routine prescribing for children who are simply above a healthy weight.
Among children receiving GLP-1 medications, 94% had severe obesity, while about 65% had obesity-related health conditions, including high blood pressure or sleep apnea.
Childhood obesity can increase the risk of metabolic and cardiovascular problems. Hence, along with lifestyle changes, doctors are increasingly looking for treatments.
One of the major concerns surrounding the findings is that the GLP-1 medications included in the study are not formally FDA-approved for weight management in children younger than 12.
However, doctors can prescribe medicines off-label when they believe there is a medical reason to do so. Clinical guidelines can also support the use of obesity medications in certain circumstances involving younger children.
The study therefore does not necessarily mean that doctors are prescribing these drugs indiscriminately. Instead, it shows how rapidly their use has expanded among children with obesity.
Also read: The Postpartum Nutrition Gap: Why New Mothers Often Neglect Their Own Health After Delivery
Dr Babak Orandi of NYU Langone Health, one of the researchers, highlighted the importance of long-term monitoring as these medications become more widely used in younger children.
He said that while the absolute numbers of children under 12 receiving GLP-1 treatment is still low, the study shows that GLP-1 use is accelerating rapidly among that age group. Orandi also said that long-term safety monitoring is needed to ensure the drugs remain safe and effective for children.
Additionally, children from higher-income households were 55% more likely to be prescribed the drugs than lower-income communities. This suggested emerging disparities in access, according to the study published in the journal Pediatrics.
"Physicians and health policymakers alike have a responsibility to ensure ... these valuable and sometimes costly treatments become available to more than those who have access to health insurance and can afford to visit pediatric clinics," said Allan Massie, co-author of the study and associate professor of surgery at NYU Grossman School of Medicine.
So even if these medicines prove to be useful for treating severe childhood obesity, access may depend partly on a family's ability to obtain the medicine, insurance coverage and treatment.
GLP-1 drugs can cause side effects like nausea, vomiting, diarrhoea and constipation. But questions around prolonged use during childhood extend beyond short-term side effects, including how treatment may affect growth, development and nutritional health over time.
Credit: AI
A compound best known for its psychedelic effects may have potential in protecting cancer patients from nerve damage caused by chemotherapy.
Researchers at the University of Texas MD Anderson Cancer Center found that psilocybin, the active psychedelic compound in 'magic mushrooms,' prevented peripheral neuropathy induced by chemotherapy in several preclinical models. The findings were published in Science recently.
It can cause burning or shooting pain, numbness, tingling, increased sensitivity to cold and loss of sensation, especially in the limbs. In some cases, the nerve damage can persist long after chemotherapy ends and may even become irreversible.
Currently, there are not a lot of options for preventing this type of nerve injury, making researchers explore other approaches that could protect nerves before chemotherapy causes damage.
Also read: Bladder Cancer Detection May Get Faster & Easier: New Urine Test Detects 92% Of Cases
In the new study, researchers tested psilocybin in multiple models involving chemotherapy drugs including cisplatin, paclitaxel and docetaxel.
They found that as few as two doses of psilocybin given before chemotherapy prevented several signs of peripheral neuropathy.
Treated models retained normal touch sensation, showed less sensitivity to cold and maintained sensory nerve endings, even after repeated chemotherapy sessions.
The researchers also found no evidence that psilocybin interfered with chemotherapy's ability to attack tumours in these models.
Also read: PM2.5 and Cancer Risk: Practical Ways to Protect Yourself in India’s Polluted Cities
According to the researchers, the answer may lie in the way nerve cells transport mitochondria, the components responsible for producing cellular energy.
Chemotherapy can disrupt this transport system, leaving nerve endings without enough energy and making them vulnerable to damage.
Psilocybin appeared to preserve mitochondrial movement through a pathway involving the serotonin 5-HT2A receptor. When researchers blocked this pathway, the protective effect disappeared.
Additionally, a non-hallucinogenic compound that activates the same receptor produced similar nerve-protective effects in the models. This suggests that the potential benefit may not depend on psilocybin's psychedelic experience itself.
Dr Moran Amit, the study's co-lead, said, "There is an urgent need for treatments that can prevent nerve injury without interfering with life-saving chemotherapy. He said the findings offer insight into protecting nerves before damage becomes persistent."
The study was conducted using laboratory and animal models, so it is not yet known whether the same protective effect will occur in people who are undergoing chemotherapy.
Researchers are now moving toward a Phase II clinical trial, known as NeuroGuard, to test whether psilocybin can prevent or reduce CIPN in people receiving chemotherapy for breast, colorectal or head and neck cancers. The trial is listed by the US National Cancer Institute as an approved Phase II study.
The trial will also examine whether preventing nerve damage could help patients tolerate their cancer treatment better and maintain quality of life.
© $2026 Times Horizon Private Limited